反応式
[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:11]2[C:19]3[C:14](=[N:15][C:16]([O:21][CH2:22][C:23](O)=[O:24])=[CH:17][C:18]=3[CH3:20])[N:13]([CH3:26])[N:12]=2)[CH:6]=[C:7]([O:9][CH3:10])[CH:8]=1.C1C=CC2N(O)N=NC=2C=1.Cl.CCN(CC)CC.[CH3:45][O:46][C:47]1[CH:52]=[CH:51][C:50]([C@@H:53]([NH2:55])[CH3:54])=[CH:49][CH:48]=1>C(Cl)Cl.O.C(Cl)CCl>[CH3:10][O:9][C:7]1[CH:6]=[C:5]([C:11]2[C:19]3[C:14](=[N:15][C:16]([O:21][CH2:22][C:23]([NH:55][C@H:53]([C:50]4[CH:51]=[CH:52][C:47]([O:46][CH3:45])=[CH:48][CH:49]=4)[CH3:54])=[O:24])=[CH:17][C:18]=3[CH3:20])[N:13]([CH3:26])[N:12]=2)[CH:4]=[C:3]([O:2][CH3:1])[CH:8]=1参加物
実験手順
To a solution of [3-(3,5-Dimethoxy-phenyl)-1,4-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yloxy]-acetic acid (building block A1, 100 mg, 0.28 mmol) in CH2Cl2 were added HOBt×H2O (64 mg, 0.42 mmol), EDC×HCl (80 mg, 0.42 mmol) and NEt3 (0.12 ml, 0.84 mmol). After stirring at rt for 5 min, (S)-1-(4-methoxyphenyl)ethanamine (64 mg, 0.42 mmol) was added and stirring continued for 18 h. Then, water was added and the mixture extracted 3 times with DCM. The organic phases were dried over Na2SO4 and the solvent removed under reduced pressure. Purification by reverse phase HPLC (Sunfire C18 OBD column) followed by liberation of the free base (SPE cartridge SCX-1, eluent 7M NH3 in methanol) yielded the title compound (17 mg, 12%). [1H-NMR (DMSO-d6, 600 MHz) δ 8.48 (d, 1H), 7.21 (d, 2H), 6.82 (d, 2H), 6.70 (s, 1H), 6.58 (s, 1H), 5.00-4.88 (m, 1H), 4.87 (d, 1H), 4.83 (d, 1H), 3.85 (s, 3H), 3.78 (s, 6H), 3.70 (s, 3H), 2.37 (s, 3H), 1.37 (d, 3H); UPLC-MS RtJ=1.14 min; [M+H]+=491.2]
後処理
- stirringstirring
- waitcontinued for 18 h
- extractionthe mixture extracted 3 times with DCM
- dry with materialThe organic phases were dried over Na2SO4
- customthe solvent removed under reduced pressure
- customPurification by reverse phase HPLC (Sunfire C18 OBD column)
出典と根拠
- ORDレコード
- ord-e6dcf59335d04c8181b79a90a5b7843a
- 出典データセット
- uspto-grants-2014_06
- 特許番号
- US08742106B2
関連ノート
読み込み中…